Premium
Oxybutynin Hydrochloride (3 mg) in the Treatment of Women with Idiopathic Detrusor Instability
Author(s) -
MOORE KATE H.,
HAY D. M.,
IMRIE A. E.,
WATSON A.,
GOLDSTEIN M.
Publication year - 1990
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1990.tb14992.x
Subject(s) - oxybutynin , placebo , crossover study , urology , medicine , detrusor instability , anesthesia , urinary incontinence , overactive bladder , alternative medicine , pathology
Summary— Oxybutynin hydrochloride (3 mg) was compared with placebo by randomised, double‐blind crossover trial in 53 females with idiopathic detrusor instability. Symptoms were cured or markedly improved in 60% of patients on oxybutynin and 2.3% on placebo. During the first treatment period, oxybutynin reduced the frequency of voiding by 35%, compared with 9% for placebo. Oxybutynin gave a significantly greater improvement than placebo in volume at the first desire to void (70 ml increase versus 7.7 ml), maximum filling‐phase detrusor pressure (17 cm H 2 O reduction versus no benefit) and cystometric capacity (104 ml increase versus 7.0 ml). A marked oxybutynin carry‐over effect was seen during the second treatment period. Side effects from the 3 mg dose of oxybutynin caused 7.5% of subjects to discontinue therapy.